bacterial resistance

Last week, a small, publicly held antibiotic biotech, Nabriva, announced that it would wind down its operations. Everyone still there lost their jobs.

This is not the MRSA pandemic, ladies and gentlemen. Let's take a look at the MRSA pandemic. In  US hospitals, even today (latest CDC data is from 2014), 46% of S.

The key problem for many struggling with the treatment of resistant infections and a paltry pipeline of new antibiotics has been the lack of a return on investment for companies trying to discover and develop new antibiotics.  In hospi

This is antibiotic awareness week. To mark this week, there has been a great deal of talk and the publication of several important papers and workshops on antibiotics and resistance.

American Council advisor, and infectious disease expert Dr. David Shlaes has been writing a blog called "Antibiotics—the Perfect Storm" since 2009.

Yesterday, we took Zeke Emanuel s and his

Normally, this wouldn t even make the news.

We at ACSH have been beating this drum for years: The world is gettin

At ACSH, we probably spend more time debunking phony or overb

Bacterial resistance is a devastating problem for healthcare even now, especially in hospitalized pat